Recruiting
Phase 1

Aripiprazole

Sponsor:

UCLA

Code:

NCT07215884

Conditions

Stuttering, Adult

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Aripiprazole 10 MG

Placebo

Study Details

Brief summary:

This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.

Conditions

Stuttering, Adult

Study ID

NCT07215884

Start date

Sep 30, 2025

Status verified date

Aug, 2026

Completion date

Aug 30, 2027

Anticipated

Primary completion date

Jun 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • native speakers of American English
  • for adults who stutter, presence of stuttering will be confirmed, with onset before age 6 years
  • Normal hearing
  • Ages of 18 to 65 years
  • healthy adults without hearing-language difficulties

Exclusion Criteria:

  • self-reported speech-language-hearing difficulties other than stuttering
  • self-reported neurological or psychological problems
  • other medications (drugs that affect dopaminergic system and/or benzodiazepines)

Study Design

Enrollment

25 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Single dose of aripiprazole

Single dose of aripiprazole, 10mg administered orally. Participant and administrator will be blinded.

placebo comparator: Placebo dose

A single placebo dose will be administered.

Interventions

Aripiprazole 10 MG

The effects of aripiprazole on stuttering and various behavioral and neural outcomes will be studied compared to placebo.

Placebo

Placebo will be compared against aripiprazole for effect on stuttering and various behavioral and neural markers.

Primary outcome measure

  • Pre-speech auditory modulation [ Time Frame: 3-4 hours after intervention dose is delivered ]
  • Speaking Induced Suppression (SIS) [ Time Frame: 3-4 hours after intervention ]
  • Centering [ Time Frame: 3-4 hours after intervention ]
  • Feedback alterations [ Time Frame: 3-4 hours after intervention ]

Central Contacts and Locations

Central contacts

Natalie Brunwin, MS

4154766888snl-bil@ucsf.edu

Locations

Biomagentic Imaging Lab

Recruiting

San Francisco, California, United States, 94143

Contacts

Natalie Brunwin, MS

415-476-6888snl-bil@ucsf.edu

Principal Investigator:

John Houde, PhD

More Information

Sponsor

University of California, San Francisco

Last update posted

Aug 19, 2026

Last verified

Aug, 2026

Keywords

  • Stuttering
  • Aripiprazole
  • Adults with Stuttering
  • Speech Fluency
  • Auditory Feedback

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-08-19.